|
1
|
Mizukami T, Izawa N, Nakajima TE and
Sunakawa Y: Targeting EGFR and RAS/RAF signaling in the treatment
of metastatic colorectal cancer: From current treatment strategies
to future perspectives. Drugs. 79:633–645. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang
Y and Li X: Exploring immunotherapy in colorectal cancer. J Hematol
Oncol. 15(95)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kim SY and Kim TW: Current challenges in
the implementation of precision oncology for the management of
metastatic colorectal cancer. ESMO Open. 5(e000634)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Beckler MD, Higginbotham JN, Franklin JL,
Ham AJ, Halvey PJ, Imasuen IE, Whitwell C, Li M, Liebler DC and
Coffey RJ: Proteomic analysis of exosomes from mutant KRAS colon
cancer cells identifies intercellular transfer of mutant KRAS. Mol
Cell Proteomics. 12:343–355. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bellier J, Nokin MJ, Caprasse M, Tiamiou
A, Blomme A, Scheijen JL, Koopmansch B, MacKay GM, Chiavarina B,
Costanza B, et al: Methylglyoxal scavengers resensitize
KRAS-mutated colorectal tumors to cetuximab. Cell Rep.
30:1400–1416. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tak E, Kim M, Cho Y, Choi S, Kim J, Han B,
Kim HD, Jang CS, Kim JE, Hong YS, et al: Expression of
neurofibromin 1 in colorectal cancer and cetuximab resistance.
Oncol Rep. 47(15)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Woolston A, Khan K, Spain G, Barber LJ,
Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y,
Newey A, et al: Transcriptomic determinants of therapy resistance
and immune landscape evolution during Anti-EGFR treatment in
colorectal cancer. Cancer Cell. 36:35–50. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Martinelli E, Ciardiello D, Martini G,
Troiani T, Cardone C, Vitiello PP, Normanno N, Rachiglio AM,
Maiello E, Latiano T, et al: Implementing anti-epidermal growth
factor receptor (EGFR) therapy in metastatic colorectal cancer:
Challenges and future perspectives. Ann Oncol. 31:30–40.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mangiapane LR, Nicotra A, Turdo A,
Gaggianesi M, Bianca P, Di Franco S, Sardina DS, Veschi V, Signore
M, Beyes S, et al: PI3K-driven HER2 expression is a potential
therapeutic target in colorectal cancer stem cells. Gut.
71:119–128. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yang YN, Zhang R, Du JW, Yuan HH, Li YJ,
Wei XL, Du XX, Jiang SL and Han Y: Predictive role of
UCA1-containing exosomes in cetuximab-resistant colorectal cancer.
Cancer Cell Int. 18(164)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang Y, Huo L, Wei Z, Tang Q and Sui H:
Hotspots and frontiers in inflammatory tumor microenvironment
research: A scientometric and visualization analysis. Front
Pharmacol. 13(862585)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Touil Y, Igoudjil W, Corvaisier M, Dessein
AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G,
et al: Cancer cells escape 5FU chemotherapy-induced cell death by
entering stemness and quiescence associated with the c-Yes/YAP
axis. Clin Cancer Res. 20:837–846. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mallini P, Lennard T, Kirby J and Meeson
A: Epithelial-to-mesenchymal transition: What is the impact on
breast cancer stem cells and drug resistance. Cancer Treat Rev.
40:341–348. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yin Z, Yu M, Ma T, Zhang C, Huang S,
Karimzadeh MR, Momtazi-Borojeni AA and Chen S: Mechanisms
underlying low-clinical responses to PD-1/PD-L1 blocking antibodies
in immunotherapy of cancer: A key role of exosomal PD-L1. J
Immunother Cancer. 9(e001698)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ji Q, Zhou L, Sui H, Yang L, Wu X, Song Q,
Jia R, Li R, Sun J, Wang Z, et al: Primary tumors release
ITGBL1-rich extracellular vesicles to promote distal metastatic
tumor growth through fibroblast-niche formation. Nat Commun.
11(1211)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Sun MY, Xu B, Wu QX, Chen WL, Cai S, Zhang
H and Tang QF: Cisplatin-resistant gastric cancer cells promote the
chemoresistance of cisplatin-sensitive cells via the exosomal
RPS3-mediated PI3K-Akt-Cofilin-1 signaling axis. Front Cell Dev
Biol. 9(618899)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tan Z, Gao L, Wang Y, Yin H, Xi Y, Wu X,
Shao Y, Qiu W, Du P, Shen W, et al: PRSS contributes to cetuximab
resistance in colorectal cancer. Sci Adv.
6(eaax5576)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cremolini C, Rossini D, Dell'Aquila E,
Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R,
Aprile G, et al: Rechallenge for patients with RAS and BRAF
wild-type metastatic colorectal cancer with acquired resistance to
first-line cetuximab and irinotecan: A phase 2 single-arm clinical
trial. JAMA Oncol. 5:343–350. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chinese Society Of Clinical Oncology Csco
Diagnosis And Treatment Guidelines For Colorectal Cancer Working
Group. Diagnosis and treatment guidelines for colorectal cancer
working group CSOCOC: Chinese society of clinical oncology (CSCO)
diagnosis and treatment guidelines for colorectal cancer 2018
(English version). Chin J Cancer Res. 31:117–134. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A (eds): AJCC cancer staging manual. 7th
edition. Springer, New York, NY, 2010.
|
|
21
|
Karnofsky DA, Abelmann WH, Craver LF and
Burchenal JH: The use of the nitrogen mustards in the palliative
treatment of carcinoma-with particular reference to bronchogenic
carcinoma. Cancer. 1:634–656. 1948.
|
|
22
|
Junjie P, Ji Z and Fangqi L: Chinese
expert consensus on the diagnosis and treatment of locally advanced
rectal cancer. Chin J Cancer. 1:41–80. 2017.(In Chinese).
|
|
23
|
National Health Commission of the People's
Republic of China. Chinese Protocol of Diagnosis and Treatment of
Colorectal Cancer (2020 edition). Zhonghua Wai Ke Za Zhi.
58:561–585. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
24
|
Lu H, Sun J, Xu JH and Fan ZZ:
Establishment of HCT116/L-OHP in oxaliplatin-resistant cells in
human colon cancer. Tumors. 31:675–681. 2011.
|
|
25
|
Sui H, Pan SF, Feng Y, Jin BH, Liu X, Zhou
LH, Hou FG, Wang WH, Fu XL, Han ZF, et al: Zuo Jin Wan reverses
P-gp-mediated drug-resistance by inhibiting activation of the
PI3K/Akt/NF-κB pathway. BMC Complement Altern Med.
14(279)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sui H, Zhou L, Zhang Y, Huang JP, Liu X,
Ji Q, Fu XL, Wen HT, Chen ZS, Deng WL, et al: Evodiamine suppresses
ABCG2 mediated drug resistance by inhibiting p50/p65/NF-κB pathway
in colorectal cancer. J Cell Biochem. 117:1471–1481.
2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang Z, Sun X, Feng Y, Liu X, Zhou L, Sui
H, Ji Q, E Q, Chen J, Wu L and Li Q: Dihydromyricetin reverses
MRP2-mediated MDR and enhances anticancer activity induced by
oxaliplatin in colorectal cancer cells. Anticancer Drugs.
28:281–288. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kim SA, Park H, Kim KJ, Kim JW, Sung JH,
Nam M, Lee JH, Jung EH, Suh KJ, Lee JY, et al: Cetuximab resistance
induced by hepatocyte growth factor is overcome by MET inhibition
in KRAS, NRAS, and BRAF wild-type colorectal cancers. J Cancer Res
Clin Oncol. 148:2995–3005. 2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chu YC, Tsai TY, Yadav VK, Deng L, Huang
CC, Tzeng YM, Yeh CT and Chen MY: 4-Acetyl-Antroquinonol B improves
the sensitization of cetuximab on both kras mutant and wild type
colorectal cancer by modulating the expression of
Ras/Raf/miR-193a-3p signaling axis. Int J Mol Sci.
22(7508)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li F, Zhan L, Dong Q, Wang Q, Wang Y, Li
X, Zhang Y and Zhang J: Tumor-derived exosome-educated hepatic
stellate cells regulate lactate metabolism of hypoxic colorectal
tumor cells via the IL-6/STAT3 pathway to confer drug resistance.
Onco Targets Ther. 13:7851–7864. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sun MY, Zhang H, Tao J, Ni ZH, Wu QX and
Tang QF: Expression and biological function of rhotekin in gastric
cancer through regulating p53 pathway. Cancer Manag Res.
11:1069–1080. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang T, Dong J, Yuan X, Wen H, Wu L, Liu
J, Sui H and Deng W: A new chalcone derivative C49 reverses
doxorubicin resistance in MCF-7/DOX cells by inhibiting
P-glycoprotein expression. Front Pharmacol.
12(653306)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Liu L, Salnikov AV, Bauer N,
Aleksandrowicz E, Labsch S, Nwaeburu C, Mattern J, Gladkich J,
Schemmer P, Werner J and Herr I: Triptolide reverses
hypoxia-induced epithelial-mesenchymal transition and stem-like
features in pancreatic cancer by NF-κB downregulation. Int J
Cancer. 134:2489–2503. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang J, Guo LP, Chen LZ, Zeng YX and Lu
SH: Identification of cancer stem cell-like side population cells
in human nasopharyngeal carcinoma cell line. Cancer Res.
67:3716–3724. 2007.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bauman JE and Grandis JR: Targeting
secondary immune responses to cetuximab: CD137 and the outside
story. J Clin Invest. 124:2371–2375. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Whiteside TL: Exosomes and tumor-mediated
immune suppression. J Clin Invest. 126:1216–1223. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Binenbaum Y, Fridman E, Yaari Z, Milman N,
Schroeder A, David GB, Shlomi T and Gil Z: Transfer of miRNA in
macrophage-derived exosomes induces drug resistance in pancreatic
adenocarcinoma. Cancer Res. 78:5287–5299. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Witwer KW, Buzás EI, Bemis LT, Bora A,
Lässer C, Lötvall J, Nolte-'t Hoen EN, Piper MG, Sivaraman S, Skog
J, et al: Standardization of sample collection, isolation and
analysis methods in extracellular vesicle research. J Extracell
Vesicles. 27(2)2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yonesaka K, Zejnullahu K, Okamoto I, Satoh
T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda
M, et al: Activation of ERBB2 signaling causes resistance to the
EGFR directed therapeutic antibody cetuximab. Sci Transl Med.
3(99ra86)2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Duan H, Liu Y, Gao Z and Huang W: Recent
advances in drug delivery systems for targeting cancer stem cells.
Acta Pharm Sin B. 11:55–70. 2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D,
Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p
functions as a tumor suppressor and novel therapeutic tool by
targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res.
74:1801–1813. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Yun JH, Kim KA, Yoo G, Kim SY, Shin JM,
Kim JH, Jung SH, Kim J and Nho CW: Phenethyl isothiocyanate
suppresses cancer stem cell properties in vitro and in a xenograft
model. Phytomedicine. 30:42–49. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Han Y, Peng Y, Fu Y, Cai C, Guo C, Liu S,
Li Y, Chen Y, Shen E, Long K, et al: MLH1 deficiency induces
cetuximab resistance in colon cancer via Her-2/PI3K/AKT signaling.
Adv Sci (Weinh). 7(2000112)2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Li H, Zhou L, Zhou J, Li Q and Ji Q:
Underlying mechanisms and drug intervention strategies for the
tumour microenvironment. J Exp Clin Cancer Res.
40(97)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Ribatti D, Mangialardi G and Vacca A:
Stephen Paget and the ‘seed and soil’ theory of metastatic
dissemination. Clin Exp Med. 6:145–149. 2006.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lièvre A, Bachet JB, Boige V, Cayre A,
Corre DL, Buc E, Ychou M, Bouché O, Landi B, Louvet C, et al: Kras
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Formica V, Sera F, Cremolini C, Riondino
S, Morelli C, Arkenau HT and Roselli M: KRAS and BRAF mutations in
Stage II and III colon cancer: A systematic review and
meta-analysis. J Natl Cancer Inst. 114:517–527. 2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Cai MH, Xu XG, Yan SL, Sun Z, Ying Y, Wang
BK and Tu YX: Regorafenib suppresses colon tumorigenesis and the
generation of drug resistant cancer stem-like cells via modulation
of miR-34a associated signaling. J Exp Clin Cancer Res.
37(151)2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS,
You JF, Hung HY, Tsai CN, Hsu A, Chen HC, et al: Mutations of
KRAS/NRAS/BRAF predict cetuximab resistance in metastatic
colorectal cancer patients. Oncotarget. 7:22257–22270.
2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Lu H, Chen I, Shimoda LA, Park Y, Zhang C,
Tran L, Zhang H and Semenza GL: Chemotherapy-induced Ca2+ release
stimulates breast cancer stem cell enrichment. Cell Rep.
18:1946–1957. 2017.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Cioffi M, D'Alterio C, Camerlingo R,
Tirino V, Consales C, Riccio A, Ieranò C, Cecere SC, Losito NS,
Greggi S, et al: Identification of a distinct population of
CD133+CXCR4+ cancer stem cells in ovarian cancer. Sci Rep.
5(10357)2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Steinbichler TB, Dudás J, Skvortsov S,
Ganswindt U, Riechelmann H and Skvortsova II: Therapy resistance
mediated by cancer stem cells. Semin Cancer Biol. 53:156–167.
2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wuebben EL and Rizzino A: The dark side of
SOX2: Cancer- a comprehensive overview. Oncotarget. 8:44917–44943.
2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Keysar SB, Le PN, Miller B, Jackson BC,
Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, et al:
Regulation of head and neck squamous cancer stem cells by PI3K and
SOX2. J Natl Cancer Inst. 109(djw189)2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Bouhaddou M, Lee RH, Li H, Bhola NE,
O'Keefe RA, Naser M, Zhu TR, Nwachuku K, Duvvuri U, Olshen AB, et
al: Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab
response in head and neck cancer. JCI Insight.
6(e151982)2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Rothenberg SM, Concannon K, Cullen S,
Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA,
Maheswaran S and Haber DA: Inhibition of mutant EGFR in lung cancer
cells triggers SOX2-FOXO6-dependent survival pathways. Elife.
4(e06132)2015.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Liu K, Lin B, Zhao M, Yang X, Chen M, Gao
A, Liu F, Que J and Lan X: The multiple roles for Sox2 in stem cell
maintenance and tumorigenesis. Cell Signal. 25:1264–1271.
2013.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Van Cutsem E, Lenz HJ, Köhne CH, Heinemann
V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken
JH and Ciardiello F: Fluorouracil, leucovorin, and irinotecan plus
cetuximab treatment and RAS mutations in colorectal cancer. J Clin
Oncol. 33:692–700. 2015.PubMed/NCBI View Article : Google Scholar
|
